Exploring the Potential of Epigallocatechin Gallate in Combating Insulin Resistance and Diabetes

Overview

Journal Nutrients

Date 2025 Jan 8

PMID 39770980

Authors

Kubra Yurtseven

Sevinc Yucecan

Affiliations

Soon will be listed here.

Abstract

Background/objectives: In this study, the potential effects are evaluated of epigallocatechin gallate (EGCG) on the prognosis of diabetes and insulin resistance.

Methods: In an experiment, 35 male Wistar albino rats were used and in the streptozotocin (STZ)-induced diabetic rats, the effects were examined of different doses (50 mg/kg, 100 mg/kg, 200 mg/kg) of EGCG on metabolic parameters associated with diabetes and insulin resistance.

Results: The findings show favorable effects of EGCG on fasting blood glucose levels, insulin secretion, insulin resistance, and beta cell function. In this study, it was observed that EGCG was able to significantly lower fasting blood glucose levels, especially at high doses (200 mg/kg), providing the most significant improvement. Furthermore, EGCG has been found to reduce insulin resistance and improve insulin sensitivity by increasing insulin secretion. When the biochemical parameters of increased insulin secretion are evaluated, it is also observed that it creates clinically significant changes. At doses of 100 mg/kg and 200 mg/kg, EGCG has the potential to help control diabetes by most effectively improving insulin resistance and beta cell function. The study results suggest that EGCG, especially at high doses, is an effective component in the treatment of diabetes and the management of insulin resistance.

Conclusions: The inclusion of EGCG as a natural flavonoid in medical nutrition therapy may contribute to glycemic control and improve insulin sensitivity in individuals with diabetes. These findings suggest that EGCG may be used as an alternative option in the treatment of diabetes and future studies may further clarify the potential benefits in this area.

References

Kim S, Kwon H, Akindehin S, Jeong H, Lee Y . Effects of Epigallocatechin-3-Gallate on Autophagic Lipolysis in Adipocytes. Nutrients. 2017; 9(7). PMC: 5537795. DOI: 10.3390/nu9070680. View

Hu H, Nakagawa T, Honda T, Yamamoto S, Mizoue T . Should insulin resistance (HOMA-IR), insulin secretion (HOMA-β), and visceral fat area be considered for improving the performance of diabetes risk prediction models. BMJ Open Diabetes Res Care. 2024; 12(1). PMC: 10806829. DOI: 10.1136/bmjdrc-2023-003680. View

Salgado A, de Carvalho L, Oliveira A, Santos V, Vieira J, Parise E . Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010; 47(2):165-9. DOI: 10.1590/s0004-28032010000200009. View

Lee S, Park S, Choi C . Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J. 2021; 46(1):15-37. PMC: 8831809. DOI: 10.4093/dmj.2021.0280. View

Zhu T, Li M, Zhu M, Liu X, Huang K, Li W . Epigallocatechin-3-gallate alleviates type 2 diabetes mellitus via β-cell function improvement and insulin resistance reduction. Iran J Basic Med Sci. 2022; 25(4):483-488. PMC: 9150804. DOI: 10.22038/IJBMS.2022.58591.13016. View

Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J. 2007; 22(3):659-61. DOI: 10.1096/fj.07-9574LSF. View

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B . IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021; 183:109119. PMC: 11057359. DOI: 10.1016/j.diabres.2021.109119. View

Legeay S, Rodier M, Fillon L, Faure S, Clere N . Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome. Nutrients. 2015; 7(7):5443-68. PMC: 4517007. DOI: 10.3390/nu7075230. View

Chan J, Lim L, Wareham N, Shaw J, Orchard T, Zhang P . The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2020; 396(10267):2019-2082. DOI: 10.1016/S0140-6736(20)32374-6. View

10.

Magliano D, Islam R, Barr E, Gregg E, Pavkov M, Harding J . Trends in incidence of total or type 2 diabetes: systematic review. BMJ. 2019; 366:l5003. PMC: 6737490. DOI: 10.1136/bmj.l5003. View

11.

Kosmas C, Bousvarou M, Kostara C, Papakonstantinou E, Salamou E, Guzman E . Insulin resistance and cardiovascular disease. J Int Med Res. 2023; 51(3):3000605231164548. PMC: 10069006. DOI: 10.1177/03000605231164548. View

12.

Heald A, Stedman M, Davies M, Livingston M, Alshames R, Lunt M . Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data. Cardiovasc Endocrinol Metab. 2020; 9(4):183-185. PMC: 7673790. DOI: 10.1097/XCE.0000000000000210. View

13.

Chandrasekaran P, Weiskirchen R . The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. Int J Mol Sci. 2024; 25(3). PMC: 10855901. DOI: 10.3390/ijms25031882. View

14.

Furman B . Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. 2015; 70:5.47.1-5.47.20. DOI: 10.1002/0471141755.ph0547s70. View

15.

Xing L, Zhang H, Qi R, Tsao R, Mine Y . Recent Advances in the Understanding of the Health Benefits and Molecular Mechanisms Associated with Green Tea Polyphenols. J Agric Food Chem. 2019; 67(4):1029-1043. DOI: 10.1021/acs.jafc.8b06146. View

16.

Wolfram S . Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr. 2007; 26(4):373S-388S. DOI: 10.1080/07315724.2007.10719626. View

17.

Haidari F, Shahi M, Zarei M, Rafiei H, Omidian K . Effect of green tea extract on body weight, serum glucose and lipid profile in streptozotocin-induced diabetic rats. A dose response study. Saudi Med J. 2012; 33(2):128-33. View

18.

Khalili D, Khayamzadeh M, Kohansal K, Ahanchi N, Hasheminia M, Hadaegh F . Are HOMA-IR and HOMA-B good predictors for diabetes and pre-diabetes subtypes?. BMC Endocr Disord. 2023; 23(1):39. PMC: 9926772. DOI: 10.1186/s12902-023-01291-9. View

19.

Kottaisamy C, Raj D, Kumar V, Sankaran U . Experimental animal models for diabetes and its related complications-a review. Lab Anim Res. 2021; 37(1):23. PMC: 8385906. DOI: 10.1186/s42826-021-00101-4. View

20.

Shahwan M, Alhumaydhi F, Ashraf G, Hasan P, Shamsi A . Role of polyphenols in combating Type 2 Diabetes and insulin resistance. Int J Biol Macromol. 2022; 206:567-579. DOI: 10.1016/j.ijbiomac.2022.03.004. View